PROCEPT BioRobotics Corporation Common Stock

PRCT's 66.8 RSI signals overbought territory despite sitting below its 52-week high, suggesting momentum may be overextended relative to fundamentals. The company trades without a P/E ratio—indicating losses—yet commands a $1.4B valuation, implying the market prices in substantial future profitability from its surgical robotics platform. With 10.86% short interest and elevated technical readings, there's potential squeeze risk if positive catalysts emerge, though unprofitable biotech/medtech names are vulnerable to sentiment shifts. The setup feels speculative: bullish on growth narrative, bearish on valuation disconnect from current earnings power.